Your email has been successfully added to our mailing list.

×
0.109842719431761 0.204972095383054 0.323249619482496 0.426433282597666 0.00202942668696099 -0.0176940639269405 -0.0487062404870624 -0.0550481988838153
Stock impact report

Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder

Therapix Biosciences Ltd American (TRPX)  More Company Research Source: PR Newswire
US:NASDAQ Investor Relations: nasdaq.com/symbol/trpx
Impact snapshot Event time: TRPX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
TRPX alerts
from News Quantified
Opt-in for
TRPX alerts

from News Quantified
Opt-in for
TRPX alerts

from News Quantified